Header Logo

Connection

Alan Go to Anticoagulants

Back to Details
This is a "connection" page, showing publications Alan Go has written about Anticoagulants.
Alan Go
Connection Strength
8.763
Anticoagulants
  1. Treatment and Outcomes of Acute Pulmonary Embolism and Deep Venous Thrombosis: The CVRN VTE Study. Am J Med. 2019 12; 132(12):1450-1457.e1.
    View in: PubMed
    Score: 0.627
  2. Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. West J Emerg Med. 2018 Mar; 19(2):346-360.
    View in: PubMed
    Score: 0.571
  3. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017 Dec 19; 167(12):845-854.
    View in: PubMed
    Score: 0.561
  4. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
    View in: PubMed
    Score: 0.323
  5. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep 01; 151(5):297-305.
    View in: PubMed
    Score: 0.318
  6. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.
    View in: PubMed
    Score: 0.313
  7. Stroke prevention in atrial fibrillation: another step sideways. Lancet. 2008 Jan 26; 371(9609):278-80.
    View in: PubMed
    Score: 0.285
  8. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008; 22(10):815-25.
    View in: PubMed
    Score: 0.283
  9. Anticoagulants for stroke prevention in atrial fibrillation: what is the right rate and where do we go from here? Nat Clin Pract Cardiovasc Med. 2005 May; 2(5):226-7.
    View in: PubMed
    Score: 0.235
  10. Decision Support Intervention and Anticoagulation for Emergency Department Atrial Fibrillation: The O'CAF? Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 04; 7(11):e2443097.
    View in: PubMed
    Score: 0.228
  11. The importance of anticoagulation management services. Manag Care. 2004 Sep; 13(9 Suppl):20-5.
    View in: PubMed
    Score: 0.225
  12. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004 Apr; 10(3 Suppl):S58-65.
    View in: PubMed
    Score: 0.218
  13. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.213
  14. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism. JAMA Netw Open. 2023 08 01; 6(8):e2328033.
    View in: PubMed
    Score: 0.208
  15. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding. J Thromb Thrombolysis. 2022 Oct; 54(3):470-479.
    View in: PubMed
    Score: 0.195
  16. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 04; 102(1):11-3.
    View in: PubMed
    Score: 0.168
  17. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34.
    View in: PubMed
    Score: 0.162
  18. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2019 12; 12(12):e007612.
    View in: PubMed
    Score: 0.162
  19. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019 07; 213:81-90.
    View in: PubMed
    Score: 0.155
  20. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 07 01; 3(3):192-197.
    View in: PubMed
    Score: 0.137
  21. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol. 2017 Sep; 40(9):746-751.
    View in: PubMed
    Score: 0.136
  22. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. J Am Geriatr Soc. 2017 Feb; 65(2):241-248.
    View in: PubMed
    Score: 0.132
  23. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 01; 65(1):35-41.
    View in: PubMed
    Score: 0.131
  24. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? Am J Cardiol. 2016 09 01; 118(5):697-9.
    View in: PubMed
    Score: 0.127
  25. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 06; 129(6):592-599.e1.
    View in: PubMed
    Score: 0.124
  26. Anticoagulation in atrial fibrillation: impact of mental illness. Am J Manag Care. 2015 Nov 01; 21(11):e609-17.
    View in: PubMed
    Score: 0.122
  27. Thrombophilia testing patterns amongst patients with acute venous thromboembolism. Thromb Res. 2015 Dec; 136(6):1160-4.
    View in: PubMed
    Score: 0.122
  28. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1.
    View in: PubMed
    Score: 0.117
  29. Intersection of cardiovascular disease and kidney disease: atrial fibrillation. Curr Opin Nephrol Hypertens. 2014 May; 23(3):275-82.
    View in: PubMed
    Score: 0.110
  30. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug; 168(2):160-7.
    View in: PubMed
    Score: 0.110
  31. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8.
    View in: PubMed
    Score: 0.104
  32. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9.
    View in: PubMed
    Score: 0.103
  33. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012 Jul; 43(7):1795-9.
    View in: PubMed
    Score: 0.095
  34. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-e575S.
    View in: PubMed
    Score: 0.094
  35. Mental illness and warfarin use in atrial fibrillation. Am J Manag Care. 2011 Sep; 17(9):617-24.
    View in: PubMed
    Score: 0.091
  36. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19; 58(4):395-401.
    View in: PubMed
    Score: 0.091
  37. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 Jan 04; 154(1):1-11.
    View in: PubMed
    Score: 0.086
  38. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17; 119(10):1363-9.
    View in: PubMed
    Score: 0.077
  39. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5.
    View in: PubMed
    Score: 0.068
  40. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006 Aug; 54(8):1231-6.
    View in: PubMed
    Score: 0.064
  41. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91.
    View in: PubMed
    Score: 0.060
  42. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis. 2005 Sep-Oct; 48(2):108-24.
    View in: PubMed
    Score: 0.060
  43. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16; 141(10):745-52.
    View in: PubMed
    Score: 0.057
  44. Effect of Screening for Undiagnosed?Atrial Fibrillation on?Stroke?Prevention. J Am Coll Cardiol. 2024 Nov 19; 84(21):2073-2084.
    View in: PubMed
    Score: 0.056
  45. Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system. BMC Cardiovasc Disord. 2023 11 21; 23(1):578.
    View in: PubMed
    Score: 0.053
  46. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26.
    View in: PubMed
    Score: 0.053
  47. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 06 20; 147(25):1891-1901.
    View in: PubMed
    Score: 0.051
  48. Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAF? trial). Trials. 2023 Mar 31; 24(1):246.
    View in: PubMed
    Score: 0.051
  49. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis. 2003 Feb; 15(1):41-6.
    View in: PubMed
    Score: 0.050
  50. Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism. Thromb Res. 2022 Aug; 216:97-102.
    View in: PubMed
    Score: 0.048
  51. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. Am Heart J. 2022 07; 249:76-85.
    View in: PubMed
    Score: 0.048
  52. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001 Sep 18; 135(6):393-400.
    View in: PubMed
    Score: 0.046
  53. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93.
    View in: PubMed
    Score: 0.042
  54. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.
    View in: PubMed
    Score: 0.037
  55. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 11; 104(22):1850-1858.
    View in: PubMed
    Score: 0.036
  56. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol. 2016 06; 9(6).
    View in: PubMed
    Score: 0.032
  57. Initial management and outcomes after superficial thrombophlebitis: The Cardiovascular Research Network Venous Thromboembolism study. J Hosp Med. 2016 06; 11(6):432-4.
    View in: PubMed
    Score: 0.031
  58. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol. 2016 Jan 26; 67(3):239-47.
    View in: PubMed
    Score: 0.031
  59. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36.
    View in: PubMed
    Score: 0.031
  60. Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. Thromb Res. 2016 Jan; 137:97-102.
    View in: PubMed
    Score: 0.031
  61. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015 Jan 01; 115(1):40-6.
    View in: PubMed
    Score: 0.028
  62. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014 Aug 15; 114(4):583-6.
    View in: PubMed
    Score: 0.028
  63. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12.
    View in: PubMed
    Score: 0.027
  64. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15; 127(2):224-32.
    View in: PubMed
    Score: 0.025
  65. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012 Sep; 9(9):1403-8.
    View in: PubMed
    Score: 0.024
  66. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):546S-592S.
    View in: PubMed
    Score: 0.018
  67. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation. 2008 Feb 26; 117(8):1101-20.
    View in: PubMed
    Score: 0.018

© 2025 Kaiser Permanente